L Wallentin

Summary

Affiliation: Uppsala University Hospital
Country: Sweden

Publications

  1. ncbi Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 27:1166-73. 2006
  2. ncbi Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Sweden
    Am Heart J 157:599-605. 2009
  3. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
  4. ncbi [Insights and views about cardiovascular safety of COX2 inhibitors]
    Lars Wallentin
    Uppsala kliniska forskningscentrum (UCR
    Lakartidningen 102:666, 668, 671. 2005
  5. ncbi Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    Lars Wallentin
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 29:21-30. 2008
  6. ncbi [Swedish work with national guidelines can become an international model. With perspectives from cardiovascular diseases guidelines]
    Lars Wallentin
    Uppsala kliniska forskningscentrum
    Lakartidningen 105:1194-7. 2008
  7. ncbi P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
    Lars Wallentin
    Uppsala Clinical Research Centre, University Hospital, Uppsala SE 75185, Sweden
    Eur Heart J 30:1964-77. 2009
  8. ncbi Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
    Lars Wallentin
    Uppsala Clinical Research Centre, University Hospital, Uppsala, Sweden
    Lancet 362:789-97. 2003
  9. ncbi Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
    L Wallentin
    Department of Cardiology and Uppsala Clinical Research Centre, Uppsala, Sweden
    Circulation 108:135-42. 2003
  10. ncbi Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:1320-8. 2010

Detail Information

Publications122 found, 100 shown here

  1. ncbi Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 27:1166-73. 2006
    ..0007). CONCLUSION: In this population, prasugrel (40-60 mg LD and 10-15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel dosing...
  2. ncbi Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Sweden
    Am Heart J 157:599-605. 2009
    ....
  3. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
    ..Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel...
  4. ncbi [Insights and views about cardiovascular safety of COX2 inhibitors]
    Lars Wallentin
    Uppsala kliniska forskningscentrum (UCR
    Lakartidningen 102:666, 668, 671. 2005
  5. ncbi Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    Lars Wallentin
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 29:21-30. 2008
    ..P2Y(12) receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable coronary artery disease...
  6. ncbi [Swedish work with national guidelines can become an international model. With perspectives from cardiovascular diseases guidelines]
    Lars Wallentin
    Uppsala kliniska forskningscentrum
    Lakartidningen 105:1194-7. 2008
  7. ncbi P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
    Lars Wallentin
    Uppsala Clinical Research Centre, University Hospital, Uppsala SE 75185, Sweden
    Eur Heart J 30:1964-77. 2009
    ..The objectives of this systematic review are to summarize the pharmacokinetics, pharmacodynamics, and pharmacogenetics of the different P2Y(12) inhibitors and to discuss the clinical implications for treatment of patients...
  8. ncbi Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
    Lars Wallentin
    Uppsala Clinical Research Centre, University Hospital, Uppsala, Sweden
    Lancet 362:789-97. 2003
    ..We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction...
  9. ncbi Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
    L Wallentin
    Department of Cardiology and Uppsala Clinical Research Centre, Uppsala, Sweden
    Circulation 108:135-42. 2003
    ..The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital reperfusion and further improve clinical outcome in patients with ST-elevation myocardial infarction...
  10. ncbi Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:1320-8. 2010
    ..CYP2C19 and ABCB1 genotypes are known to influence the effects of clopidogrel. In this substudy, we investigated the effects of these genotypes on outcomes between and within treatment groups...
  11. ncbi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:975-83. 2010
    ..We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population...
  12. ncbi Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II)
    G Frostfeldt
    Department of Cardiology, Cardiothoracic Centre, University Hospital, Uppsala, Sweden
    J Am Coll Cardiol 33:627-33. 1999
    ....
  13. ncbi Coagulation activity and clinical outcome in unstable coronary artery disease
    J Oldgren
    Department of Medical Sciences, Cardiology, University Hospital, Uppsala, Sweden
    Arterioscler Thromb Vasc Biol 21:1059-64. 2001
    ..However, this early benefit is lost during long-term follow-up when high baseline levels of coagulation activity are associated with a raised risk of early reactivation and increased mortality...
  14. ncbi Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction
    C Christersson
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    J Intern Med 270:215-23. 2011
    ..Thrombin has a role not only in the coagulation process but also in inflammatory responses. Oral direct thrombin inhibitors (DTIs) are currently being evaluated in patients with thromboembolic diseases...
  15. ncbi N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (
    Stefan K James
    Department of Medical Sciences, Cardiology, University of Uppsala, Uppsala, Sweden
    Circulation 108:275-81. 2003
    ....
  16. ncbi Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease
    L Wallentin
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Lancet 356:9-16. 2000
    ..The Fragmin and Fast Revascularisation during Instability in Coronary artery disease II trial (FRISC II) compared an early invasive with an early non-invasive strategy in unstable coronary-artery disease. We report outcome at 1 year...
  17. ncbi FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease
    B Lagerqvist
    Department of Medical Sciences, Cardiology, University Hospital, Uppsala, Sweden
    Heart 91:1047-52. 2005
    ..To develop a scoring system for risk stratification and evaluation of the effect of an early invasive strategy for treatment of unstable coronary artery disease (CAD)...
  18. ncbi Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial
    L Wallentin
    Department of Cardiology, Cardiothoracic Centre, Uppsala University Hospital, Uppsala, Sweden
    Haemostasis 30:108-13; discussion 106-7. 2000
    ..It is concluded that extended treatment with dalteparin is useful as a bridge to revascularization in this high-risk subgroup of patients with unstable coronary artery disease...
  19. ncbi Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease
    J Oldgren
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    J Intern Med 258:420-7. 2005
    ..Short-term low molecular weight (LMW) heparin treatment reduces coagulation activity and clinical events. We investigated the influence of prolonged treatment on coagulation, fibrinolysis and inflammation...
  20. ncbi Possible reasons for the prognostic value of troponin-T on admission in patients with ST-elevation myocardial infarction
    G Frostfeldt
    Department of Cardiology, Cardiothoracic Centre, University Hospital, Uppsala, Sweden
    Coron Artery Dis 12:227-37. 2001
    ..In patients with acute myocardial infarction and ST-segment elevation, increased troponin-T (TnT) on admission implies an increased mortality...
  21. ncbi Comparison between strategies using creatine kinase-MB(mass), myoglobin, and troponin T in the early detection or exclusion of acute myocardial infarction in patients with chest pain and a nondiagnostic electrocardiogram
    T Jernberg
    Department of Cardiology, Cardiothroacic Center, University Hospital, Uppsala, Sweden
    Am J Cardiol 86:1367-71, A5. 2000
    ..We conclude that a combination of creatine kinase-MB and troponin T during the first 6 hours enables early detection or exclusion of acute myocardial infarction in this population...
  22. ncbi Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction
    E Bjorklund
    Department of Cardiology, University Hospital of Uppsala, Uppsala, Sweden
    Heart 92:735-40. 2006
    ....
  23. ncbi Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy
    B Lindahl
    Department of Cardiology, University Hospital, Uppsala, Sweden
    J Am Coll Cardiol 38:979-86. 2001
    ..This study was designed to elucidate possible mechanisms for the prognostic value of troponin T (tnT)...
  24. ncbi Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain
    Kai M Eggers
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 29:2327-35. 2008
    ..We explored the usefulness of GDF-15 for early risk stratification in 479 unselected patients with acute chest pain...
  25. ncbi Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes
    S James
    Department of Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden
    Eur Heart J 23:1538-45. 2002
    ..c. dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH. Without early coronary intervention there is no indication for abciximab treatment...
  26. ncbi Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy
    E Lindmark
    Department of Medical Sciences, Clinical Chemistry, University Hospital, S-75185 Uppsala, Sweden
    JAMA 286:2107-13. 2001
    ..5% absolute reduction; P =.08). CONCLUSIONS: Circulating IL-6 is a strong independent marker of increased mortality in unstable CAD and identifies patients who benefit most from a strategy of early invasive management...
  27. ncbi Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome
    A Malarstig
    Department of Medical Sciences, Clinical Chemistry, Uppsala University, S 751 85 Uppsala, Sweden
    Heart 94:724-9. 2008
    ....
  28. ncbi Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome
    Tomas Jernberg
    Department of Medical Sciences, Cardiology, Uppsala Research Center, University Hospital, 751 85 Uppsala, Sweden
    Circulation 110:2342-8. 2004
    ..Cystatin C is a new and better marker of renal function than creatinine. The aim was therefore to evaluate the prognostic value of cystatin C in this population...
  29. ncbi Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction
    C Christersson
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    J Thromb Haemost 3:2245-53. 2005
    ....
  30. ncbi Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study
    Lars Wallentin
    Department of Medical Sciences, Cardiology, University Hospital, S 751 85, Uppsala, Sweden
    Eur Heart J 24:897-908. 2003
    ..We compared the effects of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) as an adjunct to recombinant tissue-plasminogen activator (alteplase) on coronary artery patency and clinical outcomes in AMI...
  31. ncbi ST-segment monitoring with continuous 12-lead ECG improves early risk stratification in patients with chest pain and ECG nondiagnostic of acute myocardial infarction
    T Jernberg
    Department of Cardiology, Cardiothoracic Center, University Hospital, Uppsala, Sweden
    J Am Coll Cardiol 34:1413-9. 1999
    ....
  32. ncbi Comparison of continuous vectorcardiography and continuous 12-lead electrocardiography of patients with unstable coronary artery disease: do they identify the same population?
    T Jernberg
    Department of Cardiology, Cardiothoracic Center, University Hospital, Ostra, Goteborg, Sweden
    Coron Artery Dis 12:187-95. 2001
    ..Continuous vectorcardiography (cVCG) and continuous 12-lead electrocardiography (c12ECG) are important tools for assessing patients with unstable coronary artery disease...
  33. ncbi Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden
    Stefan K James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 360:1933-45. 2009
    ..The long-term safety and efficacy of drug-eluting coronary stents have been questioned...
  34. ncbi Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators
    B Lagerqvist
    Department of Cardiology, University Hospital, Uppsala, Sweden
    J Am Coll Cardiol 38:41-8. 2001
    ....
  35. ncbi Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial
    Christina Christersson
    Department of Cardiology and Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 28:692-8. 2007
    ..e. prothrombin fragment 1 + 2 (F1 + 2) and D-dimer levels. The aim of this substudy was to evaluate the levels of these markers and activated thromboplastin time (APTT) in relation to new ischaemic events or bleeding...
  36. ncbi N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease
    Tomas Jernberg
    Department of Medical Sciences, Cardiology, Cardiothoracic Center, University Hospital, Uppsala, Sweden
    J Am Coll Cardiol 42:1909-16. 2003
    ....
  37. ncbi Observer variability and optimal criteria of transient ischemia during ST monitoring with continuous 12-lead ECG
    Tomas Jernberg
    Department of Cardiology, Cardiothoracic Center, University Hospital, 751 85 Uppsala, Sweden
    Ann Noninvasive Electrocardiol 7:181-90. 2002
    ..However, the method lacks documentation on optimal criteria for episodes of transient ischemia and on observer variability...
  38. ncbi Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy)
    Stefan K James
    Department of Medical Sciences and Cardiology, Academic Hospital, Uppsala, Sweden
    Am J Cardiol 97:167-72. 2006
    ..Despite a larger proportion of ST depression and increased levels of NT-pro-BNP and interleukin-6 at admission, these factors provide independent prognostic information that may improve risk stratification and guidance of treatment...
  39. ncbi Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome
    Anders Malarstig
    Department of Medical Sciences, Clinical Chemistry, Uppsala University, S 751 85 Uppsala, Sweden
    Arterioscler Thromb Vasc Biol 26:1667-73. 2006
    ..The aim was to investigate the prognostic importance of soluble (s) CD40L levels, single nucleotide polymorphisms (SNP) in the CD40LG gene, and the relation between sCD40L and SNPs in patients with acute coronary syndromes (ACS)...
  40. ncbi The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study
    L Wallentin
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Clin Cardiol 24:I12-4. 2001
    ..The occurrence of reinfarction was reduced during dalteparin treatment. These findings suggest that dalteparin could be substituted for UFH as an adjunct to rt-PA/aspirin in the management of patients with AMI...
  41. ncbi Low molecular weight heparin in unstable coronary artery disease
    L Wallentin
    Departments of Cardiology, University Hospital, S 75185 Uppsala, Sweden
    Expert Opin Investig Drugs 9:581-92. 2000
    ..New antiplatelet agents are also emerging as additional useful tools for treating these patients, thus it is urgent to evaluate the comibination of these new therapies with the LMWHs...
  42. ncbi Long-term management--the way forward?
    L Wallentin
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Clin Cardiol 23:I13-7. 2000
    ..Thus, dalteparin sodium appears to protect patients from cardiac events until they undergo invasive procedures, and it can therefore be used as a bridge to revascularization...
  43. ncbi Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment
    T Jernberg
    Department of Cardiology, Cardiothoracic Center, University Hospital, Uppsala, Sweden
    Eur Heart J 23:1093-101. 2002
    ....
  44. ncbi Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
    Oscar O Braun
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:626-33. 2008
    ..Attenuated platelet aggregation and reduced expression of platelet pro-coagulant and pro-inflammatory markers with prasugrel suggest the potential to reduce cardiovascular events both in the acute setting and in long-term treatment...
  45. ncbi A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes
    Stefan K James
    Department of Medical Sciences, Cardiology, Uppsala, Sweden
    Int J Cardiol 93:113-20. 2004
    ..Troponin is a specific marker of myocardial damage. For early prediction of coronary events in patients with suspicion of acute coronary syndromes the assay also needs to be highly sensitive...
  46. ncbi Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial
    Stefan James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am J Med 115:178-84. 2003
    ..However, the appropriate cutoff for identifying patients with the acute coronary syndrome who are at low risk of subsequent mortality has not been established...
  47. ncbi Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy
    Stefan K James
    Department of Medical Sciences, Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden
    Am Heart J 147:267-74. 2004
    ..In addition to platelet inhibition, recent evidence suggests that the glycoprotein IIb/IIIa receptor inhibitor abciximab attenuates inflammation and coagulation activity...
  48. ncbi Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy
    Stefan K James
    Uppsala Clinical Research Center, Uppsala, Sweden
    J Am Coll Cardiol 48:1146-54. 2006
    ..This study was designed to evaluate biomarkers for selection of patients with non-ST-segment elevation acute coronary syndromes (ACS) that derive mortality benefit from revascularization...
  49. ncbi Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease
    E Lindmark
    Laboratory for Coagulation Research, Department of Medical Sciences, Clinical Chemistry, University Hospital, S 751 85 Uppsala, Sweden
    Thromb Res 103:249-59. 2001
    ..Cellular interactions may contribute to the systemic responses observed. Women have different patterns of cellular activation than men, indicating differences in pathogenetic mechanisms...
  50. ncbi Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden
    Bo Lagerqvist
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 356:1009-19. 2007
    ..Recent reports have indicated that there may be an increased risk of late stent thrombosis with the use of drug-eluting stents, as compared with bare-metal stents...
  51. ncbi Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department Medical Sciences and Cardiology, Uppsala University, Sweden
    Am Heart J 157:562.e1-9. 2009
    ..These tests need to be evaluated in comparison to reference measurements of P2Y(12) function during different thienopyridine treatments...
  52. ncbi Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction
    Ulf Stenestrand
    Department of Cardiology, University Hospital, Linkoping, Sweden
    JAMA 296:1749-56. 2006
    ....
  53. ncbi Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Eur Heart J 30:1744-52. 2009
    ..We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel...
  54. ncbi Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy
    Bertil Lindahl
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, Uppsala, Sweden
    J Am Coll Cardiol 45:533-41. 2005
    ....
  55. ncbi Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 28:699-704. 2007
    ....
  56. ncbi Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, S 751 85 Uppsala, Sweden
    Eur Heart J 29:315-23. 2008
    ..We evaluated fondaparinux treatment vs. usual care, i.e. placebo or unfractionated (UF) heparin, in a pre-specified subgroup of 2867 (out of 12 092) patients not receiving reperfusion treatment in the OASIS-6 trial...
  57. ncbi ST2 and mortality in non-ST-segment elevation acute coronary syndrome
    Kai M Eggers
    Department of Medical Sciences, Uppsala University, Sweden
    Am Heart J 159:788-94. 2010
    ....
  58. ncbi Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy
    Stefan K James
    Department of Medical Sciences Cardiology, Thoraxcenter, Academic Hospital, 751 85 Uppsala, Sweden
    J Am Coll Cardiol 41:916-24. 2003
    ..We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS)...
  59. ncbi Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome
    Kai M Eggers
    Department of Medical Sciences, Cardiology, Uppsala University Hospital and Uppsala Clinical Research Center, Uppsala, Sweden
    Circ Cardiovasc Genet 3:88-96. 2010
    ..This study assessed the time course and the long-term prognostic relevance of GDF-15 levels measured repetitively in patients with non-ST-segment-elevation acute coronary syndrome during 6 months after the acute event...
  60. ncbi Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers
    Kai M Eggers
    Department of Medical Sciences, Cardiology, Uppsala University Hospital and Uppsala Clinical Research Center, Uppsala, Sweden
    Am Heart J 160:88-94. 2010
    ..However, there is limited knowledge regarding the utility of this score for long-term risk prediction in unselected patients with acute chest pain and whether it might be improved by the integration of nonnecrosis biomarkers...
  61. ncbi Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Uppsala University, Dag Hammarsköldsväg 14B, Science Park, Uppsala SE 751 85, Sweden
    Eur Heart J 31:3006-16. 2010
    ..We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control...
  62. ncbi Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Circulation 122:1056-67. 2010
    ....
  63. ncbi Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome
    Kai M Eggers
    Department of Medical Sciences, Cardiology, Uppsala University Hospital and Uppsala Clinical Research Centre, Uppsala, Sweden
    J Am Coll Cardiol 54:357-64. 2009
    ..The aim of this study was to assess risk prediction by different biomarkers in patients with an ongoing non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and after clinical stabilization...
  64. ncbi NT-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, University Hospital, Uppsala 751 85, Sweden
    Eur J Heart Fail 6:319-25. 2004
    ..e. unstable angina or non-ST-elevation myocardial infarction. This article focuses on the emerging role of N-terminal pro brain natriuretic peptide (NT-proBNP) and the results from the FAST, GUSTO IV and FRISC II trials...
  65. ncbi An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease
    Stefan K James
    The Research Group of Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am Heart J 149:619-26. 2005
    ..Inflammation plays an important role in unstable coronary artery disease (CAD). We assessed the kinetics of inflammatory markers from symptom onset in patients with unstable CAD and their relation to myocardial damage...
  66. ncbi The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy
    Erik Diderholm
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Am Heart J 143:760-7. 2002
    ....
  67. ncbi Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome
    Kai M Eggers
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am Heart J 156:588-94. 2008
    ..We now have studied the associations of persistently elevated cTnI levels to cardiac performance, inflammation, coagulation, coronary status, and treatment strategy in these patients...
  68. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial
    Claes Held
    Uppsala Clinical Research Center, Department of Medical Sciences, Uppsala University, Sweden
    J Am Coll Cardiol 57:672-84. 2011
    ..The purpose of this study is to evaluate the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery (CABG), as a post-randomization strategy...
  69. ncbi Non-ST-elevation acute coronary syndrome: fuel for the invasive strategy
    Lars Wallentin
    Uppsala Clinical Research Centre, University Hospital, Uppsala, S-751 85 Uppsala, Sweden
    Lancet 360:738-9. 2002
  70. ncbi Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease
    J Oldgren
    Department of Medical Sciences, Cardiology, University Hospital, Uppsala, Sweden
    Eur Heart J 24:86-93. 2003
    ..The transient elevation of C-reactive protein levels might indicate a propensity to a pronounced inflammatory response and is associated with increased mortality...
  71. ncbi Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome
    Anders Malarstig
    Department of Medical Sciences, Clinical Chemistry, Uppsala University, S 751 85 Uppsala, Sweden
    Thromb Res 119:467-73. 2007
    ..The concept of inflammation in the acute coronary syndrome (ACS) is today well established. Interleukin-6 (IL-6), a pleiotropic, proinflammatory cytokine, seems to play an important role in the development and progression of ACS...
  72. ncbi Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease
    Nina Johnston
    Department of Medical Sciences, Cardiology, Cardiothoracic Center, University Hospital, 751 85 Uppsala, Sweden
    Int J Cardiol 113:167-73. 2006
    ..The prognostic value of circulating oxidized low-density lipoprotein (OxLDL) in patients with unstable coronary artery disease (CAD) is unknown...
  73. ncbi 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study
    Bo Lagerqvist
    Department of Cardiology and Uppsala Clinical Research Center, University Hospital, S-751 85 Uppsala, Sweden
    Lancet 368:998-1004. 2006
    ..INTERPRETATION: The 5-year outcome of this trial indicates sustained benefit of an early invasive strategy in patients with non-ST-elevation acute coronary syndrome at moderate to high risk...
  74. ncbi Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease
    Nina Johnston
    Department of Medical Sciences, Cardiology, Cardiothoracic Center, University Hospital, Uppsala, Sweden
    Am Heart J 152:1052-8. 2006
    ..Few studies have investigated the effects of an early revascularization in relation to renal function in patients with unstable coronary artery disease (CAD)...
  75. ncbi Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease
    Jonas Oldgren
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Thromb Haemost 91:381-7. 2004
    ....
  76. ncbi Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy)
    Per Venge
    Department of Clinical Chemistry, University of Uppsala, Uppsala, Sweden
    Am J Cardiol 89:1035-41. 2002
    ..It is also apparent that assays with superior sensitivity, such as the Access AccuTnI, identify more patients with poor prognosis who are candidates for early invasive procedures...
  77. ncbi Prevention of cardiovascular events after acute coronary syndrome
    Lars Wallentin
    Department of Cardiology, Uppsala Clinical Research Centre, University Hospital, Uppsala, Sweden
    Semin Vasc Med 5:293-300. 2005
    ..The ESTEEM results highlight the potential for ximelagatran as an efficacious and well-tolerated long-term treatment for the prevention of arterial thrombotic events...
  78. ncbi ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery dis
    E Diderholm
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Eur Heart J 23:41-9. 2002
    ..In these patients an early invasive strategy substantially decreases death/myocardial infarction...
  79. ncbi Biochemical indicators of cardiac and renal function in a healthy elderly population
    Nina Johnston
    Department of Medical Sciences, Cardiology, University Hospital, Uppsala, Sweden
    Clin Biochem 37:210-6. 2004
    ..To examine the distributions of NT-proBNP and cystatin C and their relation to age, gender, and other physiological factors in an apparently healthy elderly population...
  80. ncbi Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction
    Gunnar Frostfeldt
    Department of Medical Science, Cardiology, University Hospital, Uppsala, Sweden
    Thromb Res 105:193-9. 2002
    ..This might be of importance as remaining high coagulation activity is associated with signs of early reocclusion and raised mortality...
  81. ncbi Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease
    Erik Diderholm
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Am J Med 115:606-12. 2003
    ..An early invasive approach after an episode of unstable coronary artery disease has beneficial effects on mortality and myocardial infarction, but its effects on exercise capacity and ischemia have not been investigated...
  82. ncbi Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study
    Rickard Carlhed
    Uppsala Clinical Research Center, University Hospital, Uppsala, Sweden
    Am Heart J 152:1175-81. 2006
    ..The intervention used a national web-based quality registry to generate local and regular real-time performance feedback...
  83. ncbi Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes
    Anders Malarstig
    Division of Clinical Chemistry, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Arterioscler Thromb Vasc Biol 25:2667-72. 2005
    ..Moreover, we wanted to investigate the impact of associated TF SNPs on mRNA production in human monocytes...
  84. ncbi A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study
    Bo Lagerqvist
    Department of Cardiology, University Hospital, Uppsala, Sweden
    J Am Coll Cardiol 40:1902-14. 2002
    ..We sought to report the first and repeat events and to separate spontaneous and procedure-related events over two years in the Fast Revascularization during InStability in Coronary artery disease (FRISC-II) invasive trial...
  85. ncbi Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial
    Erik Bjorklund
    Department of Cardiology, Thoraxcenter, University Hospital, Uppsala, Sweden
    Am Heart J 148:566-73. 2004
    ..However, a direct comparison of patients treated with fibrinolytic agents and not enrolled versus those enrolled in a trial, including a large number of patients, has not been performed...
  86. ncbi Prehospital diagnosis and start of treatment reduces time delay and mortality in real-life patients with STEMI
    Erik Bjorklund
    Department of Cardiology, University Hospital, Uppsala, Sweden
    J Electrocardiol 38:186. 2005
  87. ncbi Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers
    Nina Johnston
    The Division of Medical Sciences, Department of Cardiology, University Hospital, Uppsala, Sweden
    Am J Cardiol 97:640-5. 2006
    ....
  88. ncbi Sex, age, and clinical presentation of acute coronary syndromes
    Annika Rosengren
    Department of Medicine, Goteborg University, Sahlgrenska University Hospital, Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 25:663-70. 2004
    ..To investigate sex differences in clinical presentation in younger and older patients hospitalised with a wide spectrum of acute coronary syndromes (ACS)...
  89. ncbi Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS
    Timo Lenderink
    Department of Cardiology, Thoraxcentre, Erasmus Medical Centre, Rotterdam, The Netherlands
    Am Heart J 147:865-73. 2004
    ..Specific dosing guidelines for combination with low-molecular weight heparin must be developed for patients who subsequently will undergo a PCI...
  90. ncbi [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative]
    Anders Själander
    Medicinkliniken, Sundsvalls sjukhus
    Lakartidningen 105:2478-80. 2008
  91. ncbi ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy
    Per Johanson
    Department of Medicine Cardiology, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Am Heart J 147:853-8. 2004
    ..We have recently suggested that ST variability during the reperfusion-phase is of prognostic importance. We wanted to further investigate this and relate it to angiographic findings...
  92. ncbi Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey
    Robert C Welsh
    University of Albert, Edmonton, Canada
    Eur J Emerg Med 11:134-40. 2004
    ....
  93. ncbi [Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice]
    Stefan James
    Kardiologiska kliniken, Akademiska sjukhuset, Uppsala
    Lakartidningen 101:1514-9, 1521-2. 2004
    ....
  94. ncbi Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization
    Anna Norhammar
    Department of Cardiology, Karolinska Hospital, Stockholm, Sweden
    J Am Coll Cardiol 43:585-91. 2004
    ..This study was designed to study the influence of diabetes on the outcome of unstable coronary artery disease (CAD)...
  95. ncbi Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab
    Christophe L Dubois
    Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
    J Am Coll Cardiol 42:1178-85. 2003
    ..Although fewer patients needed urgent PCI with ABC and ENOX, clinical outcomes were less favorable in this selected population, especially with ABC...
  96. ncbi ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction
    Paul W Armstrong
    University of Alberta, Edmonton, Canada
    Eur Heart J 24:1515-22. 2003
    ..We compared ST resolution in each of the three treatment regimens in order to evaluate the speed, extent and stability of ST segment resolution and its relationship to the primary composite endpoint(s) of the trial...
  97. ncbi Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction
    Anna Norhammar
    Department of Cardiology, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Eur Heart J 24:838-44. 2003
    ..We investigated whether differences in the use of evidence-based treatment may contribute to the differences in 1-year survival in a large cohort of consecutive acute myocardial infarction patients with and without diabetes mellitus...
  98. ncbi Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation
    Christer Lidell
    Department of Cardiology, Uppsala University Hospital, Uppsala S-751 85, Sweden
    Thromb Haemost 89:842-6. 2003
    ..In conclusion, the stable anticoagulation status of patients receiving long-term warfarin therapy is unaffected by concomitant administration of clopidogrel 75 mg daily...
  99. ncbi Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
    Ronnier J Aviles
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44951, USA
    N Engl J Med 346:2047-52. 2002
    ..However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney...
  100. ncbi Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study
    Ulf Stenestrand
    Department of Cardiology, , , Sweden
    Lancet 359:1805-11. 2002
    ..Our findings lend support to the use of an invasive approach early after an acute myocardial infarction...
  101. ncbi Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment
    Maria Cecilia Bahit
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 143:205-16. 2002
    ..Oral GP IIb/IIIa inhibitors cause a paradoxic increased risk of death for unclear reasons. CONCLUSION: Further reduction of risk during the weeks after presentation with acute coronary syndromes remains an important therapeutic goal...